Buy or sell Vedanta Biosciences stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Vedanta Biosciences Stock

Vedanta Biosciences is developing a class of drugs that work by modulating the human microbiome.

Founded

2010

Headquarters

Cambridge MA, US

Total Funding

$55.4M

About Vedanta Biosciences Stock

Vedanta Biosciences was founded by PureTech and a team of world renowned experts in immunology and microbiology. Vedanta Biosciences is developing a class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. Vedanta Biosciences’ proprietary approach leverages foundational discoveries in the field of mucosal immunology to generate safe and potent treatments that restore intestinal homeostasis acting via mechanisms that are orthogonal to all existing drug classes. By modulating the microbiome with this class of drugs, we have the opportunity to treat a range of autoimmune and inflammatory diseases in potentially new ways and impact the lives of patients.

Funding History

June 2016$50.0M
November 2017$5.4M

Management

Scientific Co-Founder

Dan Littman

Scientific Co-Founder

Alexander Rudensky

Chief Executive Officer

Bernat Olle

Co-founder

David Steinberg

Co-Founder & Chair

Ruslan Medzhitov

Press

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Vedanta Biosciences or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 70K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo